Summary
DexCom, Inc. (DXCM) has announced the resolution of its ongoing global patent litigation with Abbott Diabetes Care, Inc. (Abbott). The parties entered into a comprehensive settlement and patent cross-license agreement on December 20, 2024, which effectively terminates all outstanding legal disputes concerning patent infringements and invalidation claims. This agreement is highly positive for DexCom as it eliminates significant legal costs and uncertainty associated with the protracted litigation. The terms include a royalty-free, non-exclusive, and fully paid-up license for both companies to use certain patents related to analyte sensing, including those previously contested. Furthermore, a mutual covenant not to sue is established until December 20, 2034, providing a decade of peace from further patent challenges from Abbott. This resolution allows DexCom to focus its resources and strategic efforts entirely on its business operations and innovation without the overhang of this litigation.
Key Highlights
- 1DexCom (DXCM) has settled all outstanding patent litigation with Abbott Diabetes Care, Inc.
- 2A settlement and patent cross-license agreement was executed on December 20, 2024.
- 3The agreement grants both companies royalty-free, non-exclusive, and fully paid-up licenses to specific analyte sensing patents.
- 4Neither company will owe royalties or any other financial compensation as part of the settlement.
- 5A mutual covenant not to sue is in effect until December 20, 2034, preventing patent challenges for ten years.
- 6Parties have also agreed to refrain from challenging licensed patents and patent applications for varying periods.
- 7This resolution significantly reduces legal expenses and removes uncertainty for DexCom.